Thousand Oaks, California-headquartered Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $159.6 billion, Amgen has been a pioneer in the biotechnology industry for over 40 years. Its portfolio includes treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.

While Amgen has lagged behind the broader market over the past 52 weeks, it has significantly outperformed it in 2025. AMGN stock has dropped 11.5% over the past 52 weeks and gained 13.9% in 2025, compared to the S&P 500 Index’s ($SPX) 14.5% gains over the past year and 6.1% returns on a YTD basis.

Narrowing the focus, Amgen has performed slightly better than the Health Care Select Sector SPDR Fund’s (XLV) 13.3% decline over the past year and 4.7% drop in 2025.

Amgen’s stock prices observed a marginal drop in the trading session after the release of its Q1 results on May 1; however, its performance remained robust during the quarter. Driven by new product launches and increased demand for its existing products, the company’s overall topline for the quarter surged 9.4% year-over-year to $8.2 billion, exceeding Street expectations by 2.5%. Furthermore, its adjusted EPS soared 23.7% year-over-year to $4.90, surpassing the consensus estimates by 17.8%.

For the full fiscal 2025, ending in December, analysts expect Amgen to deliver an adjusted EPS of $20.88, up 5.2% year-over-year. On a more positive note, the company has a solid earnings surprise history. It has surpassed the Street’s bottom-line projections in each of the past four quarters.

The stock has a consensus “Moderate Buy” rating overall. Of the 32 analysts covering the stock, opinions include 12 “Strong Buys,” two “Moderate Buys,” 15 “Holds,” one “Moderate Sell,” and two “Strong Sells.”

This configuration is slightly less bullish than three months ago, when 13 analysts gave “Strong Buy” recommendations.

On Jul. 27, Piper Sandler analyst David Amsellem reiterated an “Overweight” rating on AMGN and maintained a price target of $328.

Amgen’s mean price target of $316.07 suggests a 6.5% upside potential. Meanwhile, the Street-high target of $400 represents a significant 34.7% premium to current price levels.

On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com